Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 7, 2011, Pages

  Still, J Gordon ^a   Clark, Kay ^a   Degenhardt, Thorsten P ^b   Scott, Drusilla ^a   Fernandes, Prabhavathi ^a   Gutierrez, Maria J ^b  

^a Cempra Pharmaceuticals   (United States)

^b Comprehensive Phase One ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEM 102; FUSIDATE SODIUM; FUSIDIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUSIDIC ACID; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955752771     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir174     Document Type: Article

References (45)

1. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-8. (Pubitemid 36259564)
2. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74. (Pubitemid 40445022)
3. Kowalski TJ, Berbari EF, Osmon DR. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphy-lococcus aureus infections. Mayo Clin Proc 2005; 80:1201-7quiz 1208.
4. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52:113-22. (Pubitemid 40826937)
5. Panlilio AL, Culver DH, Gaynes RP, et al. The National Nosocomial Infections Surveillance System. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13:582-6.
6. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. for the EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
8. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992-June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
9. Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin- susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007; 28:273-9. (Pubitemid 46480725)
10. Styers D, Sheehan DJ, Hogan P, et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylo-coccus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.
11. Chambers HF. Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005; 352:1485-7.
12. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004; 39:47-54. (Pubitemid 38879548)
13. Grayson ML. The treatment triangle for staphylococcal infections. N Engl J Med 2006; 355:724-7.
14. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36:131-9. (Pubitemid 36143409)
15. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to van-comycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327-32. (Pubitemid 32374355)
16. Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004; 38:1049-55. (Pubitemid 38951246)
17. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-84. (Pubitemid 37505530)
18. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA. Participants in the CDC-Convened Experts' Meeting on management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available atAssessed 3 July 2008http://www.cdc.gov/ncidod/dhqp/ar-mrsa-ca.html.
19. Anderson JD. Fusidic acid: new opportunities with an old antibiotic. Can Med Assoc J 1980; 122:765-9. (Pubitemid 10147425)
20. Ernst J. Fucidin treatment of chronic staphylococcal osteitis and osteomyelitis. Acta Orthop Scand 1969; 40:677-82.
21. Hierholzer G, Rehn J, Knothe H, et al. Antibiotic therapy of chronic post-traumatic osteomyelitis. J Bone Joint Surg Br 1974; 56:721-9.
22. Pahle JA. Experiences with fucidin in the treatment of osteomyelitis. Acta Orthop Scand 1969; 40:675-84.
23. Chung HKJ, Spremulli LL. Purification and characterization of elongation factor G from bovine liver mitochondria. J Biol Chem 1990; 265:21000-4. (Pubitemid 120014111)
24. Rhomberg PR, Woosley LN, Sader HS, Jones RN. Contemporary antimicrobial activity of CEM-102 (Fusidic acid [FA]) against Canadian isolates of staphylococci and streptococci (2001-2006) [abstract 202]. Program and abstracts of the 47 Infectious Diseases Society of America Conference (Philadelphia). Chicago, IL: Infectious Diseases Society of America, 2009.
25. Dubois J, Fernandes P. In vitro activity of fusidic acid (CEM-102) against resistant strains of Staphylococcus aureus [abstract E-1561]. Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston). Washington, DC: American Society for Microbiology, 2010.
26. Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J Antimicrob Chemother 2010; 65:1353-8.
27. Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007- 2008. Antimicrob Agents Chemother 2010; 54:3614-7.
28. Canadian Pharmacists Association. Compendium of Pharmaceutical Specialties. Fucidin tablets product Monograph., 2006.
29. Leo Pharmaceutical Products Ltd. Fucidin® tablets and Fucidin suspension Australian data sheet., 2006.
30. Leo Pharma United Kingdom. Fucidin tablets SPC., 2008.
31. Goncalves J, Thorn P. Fusidic acid and the treatment of patients with skin and soft tissue infections. Eur J Clin Res 1991; 1:91-7.
32. Machet L, Puissant A, Vaillant L, et al. Treatment of skin infections with two dosages of fusidic acid (500 mg/day and 1 g/day) compared with pristinamycin 2 g/day: a multicenter randomized study. Nouv Dermatol 1994; 13:520-4. (Pubitemid 24306871)
33. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999; 12(Suppl 2):S59-66.
34. Torok E, Somogyi T, Rutkai K, et al. Fusidic acid suspension twice daily: a new treatment schedule for skin and soft tissue infection in children, with improved tolerability. J Dermatolog Treat 2004; 15:158-63. (Pubitemid 39214576)
35. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Published October 2008 Available at: http://www.wma.net/en/30publications/10policies/ b3/17c.pdf. Accessed 3 March 2011.
36. Bode KA, Donner MG, Leier I, et al. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol 2002; 64:151-8. (Pubitemid 34775185)
37. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999; 12:S23-34. (Pubitemid 29406139)
38. Tsuji BT, Bulitta JB, Forrest A, et al. Pharmacokinetics-pharmacodynamics of CEM-102 against methicillin-resistant Staphylococcus aureus using an in vitro pharmacodynamic model and mechanism-based modeling [abstract A1-1033]. Program and abstracts of the 49th Interscience Conference on antimicrobial Agents and Chemotherapy Conference (San Francisco). Washington, DC: American Society for Microbiology, 2009.
39. th Infectious Diseases Society of America Conference (Philadelphia). Chicago, IL: Infectious Diseases Society of America, 2009.
40. Tsuji BT, Okusanya OO, Bulitta JB, et al. Application of pharmaco-kinetic-pharmacodynamic modeling and justification of a novel fusidic acid dose regimen: raising Lazarus from the dead. Clin Infect Dis 2011; 52(Supp 7);S513-9.
41. Güttler F, Tybring L, Engberg-Pedersen H. Interaction of albumin and fusidic acid. Br J Pharmacol 1971; 43:151-60.
42. Reeves DS. Review: the pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987; 20:467-76.
43. Rieutord A, Bourget P, Troche G, et al. In vitro study of the protein binding of fusidic acid: a contribution to the comprehension of its pharmacokinetic behavior. Intern J Pharmaceut 1995; 119:57-64.
44. Biedenbach DJ, Rhomberg PR, Mendes, et al. Spectrum of activity, mutation rates, synergistic interactions, and effects of pH and serum proteins for fusidic acid (CEM-102). Diagn Microbiol Infect Dis 2010; 66:301-7.
45. O'Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47:647-50. (Pubitemid 32447653)